128 related articles for article (PubMed ID: 12835819)
1. [Capecitabine: an oral chemotherapeutic agent against metastatic breast and colorectal cancer].
Calzas Rodríguez J; de la Nogal Fernández B; Arrieta Garmendia JM; Lastra Aras E; García Castaño A; Barrio Gil-Fournier A; García Girón C
Farm Hosp; 2003; 27(3):171-8. PubMed ID: 12835819
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
4. Role of capecitabine (Xeloda) in breast cancer.
Kaklamani VG; Gradishar WJ
Expert Rev Anticancer Ther; 2003 Apr; 3(2):137-44. PubMed ID: 12722873
[TBL] [Abstract][Full Text] [Related]
5. [Capecitabine--a review of its antitumor activity and toxicity in clinical studies].
Sasaki T; Maeda Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1307-13. PubMed ID: 10945031
[TBL] [Abstract][Full Text] [Related]
6. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
8. [Palliative chemotherapy for metastatic breast cancer with capecitabine].
Inaba T; Kashiwaba M; Takeda Y; Komatsu H; Tomisawa Y; Takiyama I; Wakabayashi G
Gan To Kagaku Ryoho; 2009 May; 36(5):769-72. PubMed ID: 19461175
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and vinorelbine in metastatic breast cancer.
Chan A; Verrill M
Eur J Cancer; 2009 Sep; 45(13):2253-65. PubMed ID: 19464166
[TBL] [Abstract][Full Text] [Related]
10. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
Leonard RC
Br J Cancer; 2001 Jun; 84(11):1437-42. PubMed ID: 11384089
[TBL] [Abstract][Full Text] [Related]
11. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
[TBL] [Abstract][Full Text] [Related]
13. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
14. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
17. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
18. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
[TBL] [Abstract][Full Text] [Related]
19. Moving forward with capecitabine: a glimpse of the future.
Biganzoli L; Martin M; Twelves C
Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical status of capecitabine.
Schilsky RL
Oncology (Williston Park); 2000 Sep; 14(9):1297-306; discussion 1309-11. PubMed ID: 11033828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
